obefazimod
Small moleculeexperimental
Clinical trial activity
19 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
14
Phase 3
4
Phase 4
0
Earliest trial started Mar 1, 2014 (NCT02792686)
Timeline
Indications
Mechanism of action
- miR-124ACTIVATOR
miR-124 activator
- Cap binding complexMODULATOR
Cap binding complex modulator
It's antiinflammatory mechanism is thought to be due to upregulation of miR-124.
Chemistry & pharmacology
Loading structure…
SMILES
FC(F)(F)Oc1ccc(Nc2ccc3cccc(Cl)c3n2)cc1- Mol. weight
- 338.72 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297344 ↗
Also known as
- abx464
- abx464
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05507216 | Phase 3 | Nov 30, 2022 | Abivax S.A., Icahn School of Medicine at Mount Sinai, Katholieke Universiteit Leuven |
| NCT05535946 | Phase 3 | Nov 30, 2022 | Abivax S.A., Icahn School of Medicine at Mount Sinai, Katholieke Universiteit Leuven |
| NCT05507203 | Phase 3 | Oct 10, 2022 | Abivax S.A. |
| NCT05177835 | Phase 2 | Dec 3, 2021 | Abivax S.A., Katholieke Universiteit Leuven |
| NCT05032560 | Phase 1 | Sep 27, 2021 | Abivax S.A. |
| NCT05121714 | Phase 1 | Dec 17, 2020 | Abivax S.A. |
| NCT04393038 | Phase 2/Phase 3 (Phase 3) | May 1, 2020 | Abivax S.A., University of Nice Sophia Antipolis |
| NCT04023396 | Phase 2 | Oct 31, 2019 | Abivax S.A., Katholieke Universiteit Leuven |
| NCT04049448 | Phase 2 | Oct 24, 2019 | Abivax S.A. |
| NCT03905109 | Phase 2 | Jul 1, 2019 | Abivax S.A. |
| NCT03813199 | Phase 2 | Jun 30, 2019 | Abivax S.A. |
| NCT03760003 | Phase 2 | Jun 11, 2019 | Abivax S.A., Katholieke Universiteit Leuven |
| NCT03368118 | Phase 2 | Jan 20, 2018 | Abivax S.A., Orion Corporation |
| NCT03093259 | Phase 2 | Jul 1, 2017 | Abivax S.A. |
| NCT02990325 | Phase 1/Phase 2 (Phase 2) | Mar 17, 2017 | Abivax S.A. |
| NCT02735863 | Phase 2 | May 1, 2016 | Abivax S.A. |
| NCT02452242 | Phase 2 | Jan 1, 2015 | Abivax S.A. |
| NCT02731885 | Phase 1 | Sep 1, 2014 | Abivax S.A. |
| NCT02792686 | Phase 1 | Mar 1, 2014 | Abivax S.A. |
Showing 19 of 19 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Abivax S.A. | For profit | 19 | 19 | 3 | 2014 |
| Katholieke Universiteit Leuven | Academic/Hospital | 5 | 0 | 2 | 2019 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 2 | 0 | 1 | 2022 |
| Orion Corporation | For profit | 1 | 0 | 1 | 2018 |
| University of Nice Sophia Antipolis | Academic/Hospital | 1 | 0 | 1 | 2020 |
5 organizations
Page 1 / 1